Michael R Verneris Selected Research

Michael R Verneris Research Topics

Disease

28	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2022 - 06/2008
27	Leukemia 01/2022 - 03/2009
24	Graft vs Host Disease (Graft-Versus-Host Disease) 11/2021 - 06/2007
22	Neoplasms (Cancer) 01/2021 - 01/2003
19	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2021 - 06/2007
13	Hematologic Neoplasms (Hematological Malignancy) 12/2022 - 11/2010
11	Infections 01/2021 - 07/2005
8	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 06/2007
6	Residual Neoplasm 01/2021 - 06/2012
4	Inflammation (Inflammations) 12/2019 - 03/2014
3	Myeloid Leukemia (Leukemia, Myelocytic) 01/2018 - 06/2007
3	Fever (Fevers) 12/2016 - 09/2014
2	Cytokine Release Syndrome 01/2022 - 01/2018
2	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 02/2018
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 06/2007
2	Human Influenza (Influenza) 01/2017 - 01/2013
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2016 - 01/2016
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 11/2016 - 01/2010
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 10/2016 - 03/2012
2	Obesity 01/2016 - 02/2009
2	Neutropenia 10/2015 - 09/2014
2	Lymphoma (Lymphomas) 12/2012 - 01/2003
2	Philadelphia Chromosome 06/2012 - 12/2009
1	Juvenile Myelomonocytic Leukemia 11/2021
1	Chickenpox 01/2021
1	Measles 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Mumps 01/2021
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2020
1	Cytopenia 01/2020
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2020
1	Central Nervous System Neoplasms 10/2019
1	Primary Immunodeficiency Diseases 01/2019
1	HIV Infections (HIV Infection) 05/2018

Drug/Important Bio-Agent (IBA)

7	Chimeric Antigen ReceptorsIBA 12/2022 - 01/2018
7	tisagenlecleucelIBA 12/2022 - 01/2018
6	LigandsIBA 11/2021 - 06/2007
5	CytokinesIBA 01/2021 - 12/2012
4	EndoglinIBA 10/2020 - 06/2015
4	AntigensIBA 10/2018 - 01/2016
3	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 01/2020
3	Glucose (Dextrose)FDA LinkGeneric 11/2020 - 01/2016
3	Proteins (Proteins, Gene)FDA Link 10/2018 - 06/2014
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2018 - 09/2007
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2022 - 07/2013
2	fludarabineIBA 12/2022 - 01/2018
2	blinatumomabIBA 12/2021 - 01/2019
2	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021 - 01/2020
2	Polysaccharides (Glycans)IBA 01/2021 - 04/2012
2	carotuximabIBA 10/2020 - 01/2017
2	Transforming Growth Factors (Transforming Growth Factor)IBA 10/2020 - 01/2017
2	Monoclonal AntibodiesIBA 10/2020 - 01/2017
2	KIR ReceptorsIBA 01/2020 - 05/2010
2	FollistatinIBA 01/2020 - 06/2015
2	Biomarkers (Surrogate Marker)IBA 12/2019 - 02/2009
2	Biological ProductsIBA 01/2019 - 05/2013
2	HLA-A Antigens (HLA-A)IBA 01/2019 - 10/2016
2	LeptinIBA 01/2019 - 06/2015
2	Epidermal Growth Factor (EGF)IBA 02/2018 - 06/2015
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2018 - 11/2016
2	DNA (Deoxyribonucleic Acid)IBA 09/2014 - 05/2013
2	Interleukin-2 (IL2)IBA 06/2014 - 12/2005
2	ChemokinesIBA 03/2014 - 12/2012
2	Messenger RNA (mRNA)IBA 02/2014 - 04/2012
2	HLA Antigens (Human Leukocyte Antigens)IBA 11/2010 - 11/2009
1	CD19-specific chimeric antigen receptorIBA 01/2022
1	Isoantigens (Alloantigen)IBA 10/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	VaccinesIBA 01/2021
1	CD19 AntigensIBA 01/2021
1	CXC ChemokinesIBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	daratumumabIBA 01/2020
1	SteroidsIBA 12/2019
1	Interferon Type IIBA 12/2019
1	DioxygenasesIBA 01/2019
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2019
1	AdipokinesIBA 01/2019
1	AdiponectinIBA 01/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019
1	Surface Antigens (Surface Antigen)IBA 10/2018
1	ErbB Receptors (EGF Receptor)IBA 02/2018
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 02/2018
1	Membrane Proteins (Integral Membrane Proteins)IBA 02/2018
1	Immunotoxins (Immunotoxin)IBA 02/2018
1	Urokinase Plasminogen Activator ReceptorsIBA 02/2018
1	treosulfanIBA 01/2018

Therapy/Procedure

35	Cell Transplantation 11/2021 - 07/2005
26	Transplantation 11/2021 - 03/2009
22	Therapeutics 01/2022 - 01/2003
14	Drug Therapy (Chemotherapy) 12/2022 - 01/2003
6	Immunotherapy 01/2022 - 12/2005
6	Hematopoietic Stem Cell Transplantation 12/2019 - 05/2011
3	Homologous Transplantation 01/2020 - 03/2009
2	Stem Cell Transplantation 10/2019 - 01/2017
1	Glycemic Control 11/2020
1	Critical Care (Surgical Intensive Care) 11/2020
1	Aftercare (After-Treatment) 02/2018